DNA is the molecular target for many of the drugs that are used in cancer therapeutics. Of particular interest are the minor groove binders, a group of DNA interactive agents that bind to specific regions of the genome and show significant toxicity towards cancer cells [1].
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Alkylating agents induce permanent DNA damage and exhibit potent antitumor activity. A range of alkylating agents is known including monoalkylating and bifunctional alkylating drugs. The latter were found to crosslink the two complementary strands of DNA, which usually results in more efficacious agents.
New chiral 1H,3H-pyrrolo[1,2-c]thiazoles were synthesized and screened for their in vitro activity as anticancer agents in three human tumor cell lines, colorectal adenocarcinoma, melanoma and breast adenocarcinoma. (R)-6-Hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo [1,2-c]thiazole and the corresponding benzylcarbamate showed selectivity for breast cancer cell lines with IC 50 values of 2.4 μM and 2.2 μM, respectively. The latter also showed significant activity against colorectal adenocarcinoma cancer cell lines (IC 50 = 8.7 μM). In contrast, the 7-hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo [1,2-c]thiazole gave moderate anticancer activity. The performance against breast cancer cell lines (IC 50 = 1.0 μM) of a potential bisalkylating agent, a (3R)-6,7-bis (hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole, wasn't significantly different from the one observed for the monoalkylanting derivatives indicating that the main mechanism of action may in fact be the monoalkylation process.
